Xu G, Liu B, Sun Y et al (2018) Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. BMJ 362:k1497. https://doi.org/10.1136/bmj.k1497
Article
PubMed
PubMed Central
Google Scholar
Saeedi P, Petersohn I, Salpea P, et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843
Defronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4):773–795. https://doi.org/10.2337/db09-9028
CAS
Article
PubMed
PubMed Central
Google Scholar
Stein SA, Lamos EM, Davis SN (2013) A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 12(2):153–175. https://doi.org/10.1517/14740338.2013.752813
CAS
Article
PubMed
Google Scholar
Shippey EA, Wagler VD, Collamer AN (2018) Hydroxychloroquine: an old drug with new relevance. Cleve Clin J Med 85(6):459–467. https://doi.org/10.3949/ccjm.85a.17034
Article
PubMed
Google Scholar
Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG (2015) Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia 58(10):2336–2343. https://doi.org/10.1007/s00125-015-3689-2
CAS
Article
PubMed
PubMed Central
Google Scholar
Sheikhbahaie F, Amini M, Gharipour M, Aminoroaya A, Taheri N (2016) The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition. Adv Biomed Res 5:145. https://doi.org/10.4103/2277-9175.187401
CAS
Article
PubMed
PubMed Central
Google Scholar
Bajaj S (2018) RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. Int J Diabetes Dev Ctries 38(Suppl 1):1–115. https://doi.org/10.1007/s13410-018-0604-7
Article
PubMed
Google Scholar
Das AK, Kalra S, Tiwaskar M, Bajaj S et al (2019) Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D). J Assoc Physicians India 67(12):65–74
CAS
PubMed
Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535
Article
PubMed
PubMed Central
Google Scholar
Baidya A, Ahmed R (2018) Effect of early addition of hydroxychloroquine in type 2 diabetic patients inadequately controlled on metformin and sulfonylurea combination therapy. Int J Res Med Sci 6:2626–2632
Article
Google Scholar
Baidya A, Kumar M, Kumar Pathak S, Ahmed R (2018) Study of comparative effect of hydroxychloroquine and vildagliptin on glycaemic efficacy and HbA1c in type 2 diabetes patients who were inadequately controlled with metformin and glimepiride dual therapy. JMSCR 6:409–415
Chakravarti HN, Nag A (2020) Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. J Endocrinol Invest 1–12 https://doi.org/10.1007/s40618-020-01330-5
Hsia SH, Duran P, Lee ML, Davidson MB (2020) Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: a pilot study. J Diabetes 12(1):91–94. https://doi.org/10.1111/1753-0407.12989
CAS
Article
PubMed
Google Scholar
Kumar V, Singh MP, Singh AP et al (2018) Efficacy and safety of hydroxychloroquine when added to stable insulin therapy in combination with metformin and glimepiride in patients with type 2 diabetes compare to sitagliptin. Int J Basic Clin Pharmacol 7:1959–1964 https://doi.org/10.18203/2319-2003.ijbcp20183930
Pareek A, Chandurkar N, Thomas N et al (2014) Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin 30(7):1257–1266. https://doi.org/10.1185/03007995.2014.909393
CAS
Article
PubMed
Google Scholar
Pareek A, Chandurkar N, Thulaseedharan NK et al (2015) Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. Curr Med Res Opin 31(11):2105–2117. https://doi.org/10.1185/03007995.2015.1087989
CAS
Article
PubMed
Google Scholar
Ranjan P, Ahsan S, Bhushan R, KumarTushar BGA et al (2018) Comparison of efficacy and safety of hydroxychloroquine and teneligliptin in type 2 diabetes patients who are inadequately controlled with glimepiride, metformin and insulin therapy: a randomized controlled trial with parallel group design. Ann Clin Endocrinol Metabol 2:033–040. https://doi.org/10.29328/journal.acem.1001009
Article
Google Scholar
Solomon DH, Garg R, Lu B et al (2014) Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken) 66(8):1246–1251. https://doi.org/10.1002/acr.22285
CAS
Article
Google Scholar
Zannah S, Islam M, Rahman A et al (2014) Antidiabetic drugs in combination with hydroxychloroquine improve glycemic control in alloxan induced diabetic rats. Pharmacol Pharm 5:725–735. https://doi.org/10.4236/pp.2014.57082
CAS
Article
Google Scholar
Singh UP, Baidya A, Singla M et al (2018) Efficacy and safety of substituting teneligliptin with hydroxychloroquine in inade- quately controlled type II diabetes subjects with combination therapy of teneligliptin, metformin, and glimepiride with or without other antidiabetic therapy: the TENE-HYQ SHIFT Study. Clin Diabetol 7:209–214
CAS
Article
Google Scholar
Singh UP, Jain S, Singla M et al (2018) Comparison between the clinical efficacy and safety of hydroxychloroquine and sitagliptin added to inadequately controlled with glimepiride and metformin in Indian patients with type 2 diabetes mellitus: a real-world observational study. EC Endocrinol Metab Res 3:147–155
Google Scholar
Wondafrash DZ, Desalegn TZ, Yimer EM, Tsige AG, Adamu BA, Zewdie KA (2020) Potential effect of hydroxychloroquine in diabetes mellitus: a systematic review on preclinical and clinical trial studies. J Diabetes Res 2020:5214751. https://doi.org/10.1155/2020/5214751
CAS
Article
PubMed
PubMed Central
Google Scholar
Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF (2015) Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23(5):231–269. https://doi.org/10.1007/s10787-015-0239-y
CAS
Article
PubMed
Google Scholar
Infante M, Ricordi C, Fabbri A (2020) Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: risks and benefits at the time of COVID-19 pandemic. J Diabetes 12(9):659–667. https://doi.org/10.1111/1753-0407.13053
CAS
Article
PubMed
Google Scholar
Paul H (2018) Managing uncontrolled type 2 diabetes: role of hydroxychloroquine in therapy as AD on antidiabetic agent: a case study. EC Endocrinol Metabol Res 3:84–88
Google Scholar
Emami J, Gerstein HC, Pasutto FM, Jamali F (1999) Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Can J Physiol Pharmacol 77(2):118–123
CAS
Article
Google Scholar
Chakravorty S, Purkait I, Pareek A, Talware A (2017) Hydroxychloroquine: looking into the future. Rom J Diabetes Nutr Metab Dis 24:369–375
Article
Google Scholar
Halaby MJ, Kastein BK, Yang DQ (2013) Chloroquine stimulates glucose uptake and glycogen synthase in muscle cells through activation of Akt. Biochem Biophys Res Commun 435(4):708–713. https://doi.org/10.1016/j.bbrc.2013.05.047
CAS
Article
PubMed
Google Scholar